ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA,” the "Company,” or "we”), an end-to-end commercial biopharmaceutical company ...

Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth –– Total ...

New data for investigational nipocalimab in Sjögren's Disease (SjD) and new research on the impact of TREMFYA® (guselkumab) in psoriatic arthritis (PsA) will be highlighted across three oral sessions ...